

Release Notes for the TJC2022B Manual

Measure Information Forms

Section	Rationale	Description
ACHF-01	<p>Updated left ventricular ejection fraction (LVEF) to ≤40% to align with the AHA / ACC heart failure guidelines.</p>	<p>Updated Measure Description</p> <p>Change From:</p> <p>Description: Beta-blocker therapy (i.e., bisoprolol, carvedilol, or sustained-release metoprolol succinate) is prescribed for heart failure patients with LVSD at discharge. For purposes of this measure, LVSD is defined as chart documentation of a left ventricular ejection fraction (LVEF) less than 40% or a narrative description of left ventricular systolic (LVS) function consistent with moderate or severe systolic dysfunction.</p> <p>Change To: Description: Beta-blocker therapy (i.e., bisoprolol, carvedilol, or sustained-release metoprolol succinate) is prescribed for heart failure patients with LVSD at discharge. For purposes of this measure, LVSD is defined as chart documentation of a left ventricular ejection fraction (LVEF) ≤40% or a narrative description of left ventricular systolic (LVS) function consistent with moderate or severe systolic dysfunction.</p> <p>Denominator Statement Change From: Denominator Statement: Heart failure patients with current or prior documentation of left ventricular ejection fraction (LVSD) < 40%.</p> <p>Change To: Denominator Statement: Heart failure patients with current or prior documentation of left ventricular ejection fraction (LVSD) ≤40%.</p> <p>Denominator Included Populations</p> <p>Change From:</p>

